JO3466B1 - مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 - Google Patents

مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6

Info

Publication number
JO3466B1
JO3466B1 JOP/2014/0369A JOP20140369A JO3466B1 JO 3466 B1 JO3466 B1 JO 3466B1 JO P20140369 A JOP20140369 A JO P20140369A JO 3466 B1 JO3466 B1 JO 3466B1
Authority
JO
Jordan
Prior art keywords
gpr6
modulators
tetrahydropyridopyrazines
compounds
intermediates
Prior art date
Application number
JOP/2014/0369A
Other languages
English (en)
Inventor
Shota Kikuchi
Jason Brown
Huikai Sun
Holger Monenschein
Maria Hopkins
Todd Macklin
Holly Reichard
Stephen Hitchcock
Kristin Schleicher
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52440811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3466(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3466B1 publication Critical patent/JO3466B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يوفر الاختراع الحالي مركبات من الصيغة 1: 1 التي تكون مفيدة كمواد ضابطة (modulators)GPR6، تركيبات دوائية من هذا، طرق لمعالجة حالات مصاحبة مع GPR6، عمليات لصنع المركبات والمركبات الوسطية من هذا.
JOP/2014/0369A 2013-12-20 2014-12-18 مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 JO3466B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361919661P 2013-12-20 2013-12-20

Publications (1)

Publication Number Publication Date
JO3466B1 true JO3466B1 (ar) 2020-07-05

Family

ID=52440811

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0369A JO3466B1 (ar) 2013-12-20 2014-12-18 مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6

Country Status (41)

Country Link
US (4) US9181249B2 (ar)
EP (2) EP3083620B1 (ar)
JP (1) JP6538697B2 (ar)
KR (1) KR102441531B1 (ar)
CN (2) CN105829309B (ar)
AR (2) AR098872A1 (ar)
AU (1) AU2014368992C1 (ar)
BR (1) BR112016014020B1 (ar)
CA (1) CA2934247C (ar)
CL (1) CL2016001595A1 (ar)
CR (1) CR20160321A (ar)
CY (1) CY1121395T1 (ar)
DK (1) DK3083620T3 (ar)
DO (1) DOP2016000144A (ar)
EA (1) EA032443B1 (ar)
EC (1) ECSP16061758A (ar)
ES (1) ES2702187T3 (ar)
GE (1) GEP201706783B (ar)
HR (1) HRP20182004T1 (ar)
HU (1) HUE042443T2 (ar)
IL (1) IL246177B (ar)
JO (1) JO3466B1 (ar)
LT (1) LT3083620T (ar)
MA (1) MA39193B1 (ar)
MX (1) MX2016008188A (ar)
MY (1) MY177031A (ar)
NZ (1) NZ721723A (ar)
PE (1) PE20160751A1 (ar)
PH (1) PH12016501192B1 (ar)
PL (1) PL3083620T4 (ar)
PT (1) PT3083620T (ar)
RS (1) RS58092B1 (ar)
SG (1) SG11201604921TA (ar)
SI (1) SI3083620T1 (ar)
TN (1) TN2016000244A1 (ar)
TR (1) TR201900038T4 (ar)
TW (2) TWI809395B (ar)
UA (1) UA120427C2 (ar)
UY (1) UY35908A (ar)
WO (1) WO2015095728A1 (ar)
ZA (1) ZA201604703B (ar)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8629274B2 (en) 2011-12-21 2014-01-14 Novira Therapeutics, Inc. Hepatitis B antiviral agents
WO2014028479A1 (en) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
JP2015533782A (ja) 2012-08-28 2015-11-26 ヤンセン・サイエンシズ・アイルランド・ユーシー スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
EP2961732B1 (en) 2013-02-28 2017-04-12 Janssen Sciences Ireland UC Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US10450270B2 (en) 2013-07-25 2019-10-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CN106232136A (zh) 2014-02-05 2016-12-14 诺维拉治疗公司 用于治疗hbv感染的联合疗法
AU2015214961B2 (en) 2014-02-06 2018-08-30 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2015123505A1 (en) * 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
JP2018510159A (ja) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
WO2019175657A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
MX2021013594A (es) 2019-05-06 2021-12-10 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2195768A1 (en) * 1994-08-11 1996-02-22 Shuji Hinuma G protein coupled receptor protein, production, and use thereof
AU6453501A (en) * 1999-02-26 2001-09-03 Arena Pharmaceuticals, Inc. Small molecule modulators of G protein-coupled receptor six
WO2001070269A1 (fr) 2000-03-24 2001-09-27 Akzo Nobel N.V. Inhibiteurs de la croissance des keratinocytes et derives d'acide hydroxamique
AU2003274005A1 (en) * 2002-10-24 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
WO2004069162A2 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2007242555B2 (en) * 2006-04-21 2010-12-16 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
CA2688471C (en) 2007-06-05 2017-01-17 Astrium Limited Remote testing system and method
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
GB2449929A (en) 2007-06-08 2008-12-10 Snell & Wilcox Ltd Hierarchical spatial resolution building processes to fill holes in an interpolated image
JP6041671B2 (ja) 2009-06-12 2016-12-14 アビバックス ガンを治療する為に有用な化合物
WO2013087808A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
WO2013087815A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof
CA2872883A1 (en) 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2014028479A1 (en) * 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
FR2995937B1 (fr) 2012-09-21 2014-09-26 Exoes Ensemble de production d'electricite a moteur a pression de vapeur
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6

Also Published As

Publication number Publication date
JP6538697B2 (ja) 2019-07-03
GEP201706783B (en) 2017-11-27
AR129635A2 (es) 2024-09-11
HRP20182004T1 (hr) 2019-02-08
HUE042443T2 (hu) 2019-06-28
CN108658978A (zh) 2018-10-16
US20180346464A1 (en) 2018-12-06
IL246177B (en) 2019-11-28
PH12016501192A1 (en) 2016-08-15
US10077266B2 (en) 2018-09-18
BR112016014020A8 (pt) 2018-01-30
MY177031A (en) 2020-09-02
US9708313B2 (en) 2017-07-18
PT3083620T (pt) 2019-01-17
US20160031881A1 (en) 2016-02-04
US10738046B2 (en) 2020-08-11
TWI730937B (zh) 2021-06-21
MA39193A1 (fr) 2017-06-30
TW201605854A (zh) 2016-02-16
TR201900038T4 (tr) 2019-01-21
KR102441531B1 (ko) 2022-09-07
BR112016014020B1 (pt) 2023-02-28
AU2014368992B2 (en) 2018-09-13
AR098872A1 (es) 2016-06-22
KR20160099705A (ko) 2016-08-22
JP2017502027A (ja) 2017-01-19
ZA201604703B (en) 2018-11-28
MA39193B1 (fr) 2018-04-30
RS58092B1 (sr) 2019-02-28
AU2014368992C1 (en) 2019-02-21
CA2934247C (en) 2023-01-17
US20150175602A1 (en) 2015-06-25
EP3453709A1 (en) 2019-03-13
IL246177A0 (en) 2016-08-02
PL3083620T3 (pl) 2019-09-30
CR20160321A (es) 2016-09-28
US20170283414A1 (en) 2017-10-05
MX2016008188A (es) 2016-09-29
SG11201604921TA (en) 2016-07-28
UA120427C2 (uk) 2019-12-10
TN2016000244A1 (en) 2017-10-06
AU2014368992A1 (en) 2016-07-07
US9181249B2 (en) 2015-11-10
ES2702187T3 (es) 2019-02-27
CY1121395T1 (el) 2020-05-29
CL2016001595A1 (es) 2017-01-13
EP3083620B1 (en) 2018-10-03
EA201691272A1 (ru) 2017-05-31
CA2934247A1 (en) 2015-06-25
PH12016501192B1 (en) 2016-08-15
SI3083620T1 (sl) 2019-02-28
PE20160751A1 (es) 2016-08-01
CN105829309B (zh) 2018-05-15
ECSP16061758A (es) 2018-02-28
TW202202497A (zh) 2022-01-16
LT3083620T (lt) 2019-02-11
TWI809395B (zh) 2023-07-21
EA032443B1 (ru) 2019-05-31
NZ721723A (en) 2021-07-30
WO2015095728A1 (en) 2015-06-25
DK3083620T3 (en) 2019-01-14
PL3083620T4 (pl) 2019-09-30
BR112016014020A2 (pt) 2017-08-08
UY35908A (es) 2015-07-31
CN105829309A (zh) 2016-08-03
EP3083620A1 (en) 2016-10-26
DOP2016000144A (es) 2016-08-15

Similar Documents

Publication Publication Date Title
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12018500718A1 (en) Compounds useful as modulators of trpm8
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
JO3719B1 (ar) 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
MX2017007377A (es) Compuestos organicos.
IN2013MU00848A (ar)
EP3795578A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
PH12016501613A1 (en) Pyrazines modulators of gpr6
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2017007380A (es) Compuestos organicos.
SG10201803880TA (en) Stable compositions of neuroactive peptides
MX338113B (es) Proceso para la preparacion de polisulfonato de sodio del 5,14-dihidrotetraazapentaceno e intermediarios de los mismos.
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
IN2014MU00197A (ar)
IN2013CH05591A (ar)
IN2013MU01524A (ar)
IN2014MU00069A (ar)
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
IN2013CH05395A (ar)
IN2013DE03592A (ar)